Insulet Corporation (PODD) is well-poised to gain in the coming quarters, backed by the strength of its revolutionary Omnipod 5 Automated Insulin Delivery (“AID”) system. The continued market expansion of Omnipod DASH is also highly encouraging.  Strong solvency is an added upside.  Meanwhile, the company’s sole dependency on the Omnipod system and intense competitive pressure remain concerns for its operations.  In the past year, this Zacks Rank #2 (Buy) stock has decreased 47.9% against the 6.6% rise of t ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.It also includes access to the Zacks Style Scores.W ...

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today presented positive results from its first randomized controlled trial (RCT) showing improved glycemic and patient-reported outcomes in type 1 diabetes with the Omnipod 5 Automated Insulin Delivery System (Omnipod 5). The OP5-003 Trial results were presented at the 17th International Conference on Advanced Technologies & T ...

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, will present new clinical evidence related to the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) taking place March 6 – 9, 2024 in Florence, Italy, and online. “We are thrilled to unveil the results of our inaugural random ...

Insulet Corporation (PODD) reported adjusted earnings per share (EPS) of $1.40 for fourth-quarter 2023, which improved from the year-ago period’s adjusted EPS of 52 cents per share.Fourth-quarter 2023 adjusted earnings exceeded the Zacks Consensus Estimate of 67 cents by a huge 108.9%.The quarter’s adjustment excludes a charge associated with a voluntary medical device correction notice issued to replace the Omnipod DASH Personal Diabetes Managers.GAAP EPS for the quarter was $1.44 compared with 24 cents in ...

Insulet (PODD) has been beaten down lately with too much selling pressure. While the stock has lost 15.3% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier.Here is How to Spot Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator that measu ...

Insulet Corporation (NASDAQ:PODD) Q4 2023 Results Conference Call February 22, 2024 4:30 PM ET Company Participants Deborah Gordon - Vice President, Investor Relations Jim Hollingshead - President & Chief Executive Officer Lauren Budden - Interim Chief Financial Officer & Treasurer Conference Call Participants Travis Steed - Bank of America Rohin Patel - JPMorgan Jeff Johnson - Baird Jayson Bedford - Raymond James Larry Biegelsen - Wells Fargo Margaret Kaczor - William Blair Josh Jennings - TD Cowen Matthew ...

Insulet (PODD) reported $509.8 million in revenue for the quarter ended December 2023, representing a year-over-year increase of 37.9%. EPS of $1.40 for the same period compares to $0.55 a year ago.The reported revenue represents a surprise of +10.79% over the Zacks Consensus Estimate of $460.17 million. With the consensus EPS estimate being $0.67, the EPS surprise was +108.96%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall St ...

Insulet (PODD) came out with quarterly earnings of $1.40 per share, beating the Zacks Consensus Estimate of $0.67 per share. This compares to earnings of $0.55 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 108.96%. A quarter ago, it was expected that this maker of insulin infusion systems would post earnings of $0.40 per share when it actually produced earnings of $0.71, delivering a surprise of 77.50%.Over the last four qua ...

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months and full year ended December 31, 2023. Full Year Financial Highlights: Full year 2023 revenue of $1.7 billion, up 30.0%, or 29.6% in constant currency, compared to $1.3 billion in the prior year, exceeds the guidance range of 26% to 27% in constant currency. Full year ...